This innovative discovery provides a solid experimental foundation for the development of safe and effective ATP1A2-targeted therapeutic strategies, facilitating the precise and personalized treatment of bladder cancer in the future. This evidence concerns the gene ATP1A2 and urinary bladder cancer.